APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Ustekinumab Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Ustekinumab Biosimilars Market Outlook and Growth Opportunities 2026

Report ID 174044730427 December 2025194 pages

Choose your research edition.

Industry ResearchUstekinumab Biosimilars Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Ustekinumab Biosimilars Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Ustekinumab Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ustekinumab Biosimilars Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Ustekinumab Biosimilars Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Ustekinumab Biosimilars market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Ustekinumab Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Ustekinumab Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Ustekinumab Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Ustekinumab Biosimilars market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Ustekinumab Biosimilars market include Teva, Amgen, Samsung Bioepis, Sandoz, Biocon Biologics, Celltrion, Qyuns Therapeutics, Bio-Thera Solutions and Huadong Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Ustekinumab Biosimilars market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Ustekinumab Biosimilars and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Ustekinumab Biosimilars sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Ustekinumab Biosimilars market size, projected growth trends, production technologies, key applications, and end-use industries.

Ustekinumab Biosimilars Segment by Company

Teva

Amgen

Samsung Bioepis

Sandoz

Biocon Biologics

Celltrion

Qyuns Therapeutics

Bio-Thera Solutions

Huadong Medicine

Ustekinumab Biosimilars Segment by Type

Subcutaneous Injection

Intravenous Infusion

Ustekinumab Biosimilars Segment by Application

Crohn's Disease

Ulcerative Colitis

Plaque Psoriasis

Psoriatic Arthritis

Other

Ustekinumab Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Ustekinumab Biosimilars status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Ustekinumab Biosimilars market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Ustekinumab Biosimilars significant trends, drivers, influence factors in global and regions.

6. To analyze Ustekinumab Biosimilars competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ustekinumab Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ustekinumab Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ustekinumab Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Ustekinumab Biosimilars market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Ustekinumab Biosimilars industry.

Chapter 3: Detailed analysis of Ustekinumab Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Ustekinumab Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Ustekinumab Biosimilars in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Ustekinumab Biosimilars Industry Trends Table 2. Ustekinumab Biosimilars Industry Drivers Table 3. Ustekinumab Biosimilars Industry Opportunities and Challenges Table 4. Ustekinumab Biosimilars Industry Restraints Table 5. Global Ustekinumab Biosimilars Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Ustekinumab Biosimilars Revenue Share by Company (2021-2026) Table 7. Global Ustekinumab Biosimilars Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Ustekinumab Biosimilars Sales Volume Share by Company (2021-2026) Table 9. Global Ustekinumab Biosimilars Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Ustekinumab Biosimilars Company Ranking, (2024-2026) & (USD Million) Table 11. Global Ustekinumab Biosimilars Key Company Manufacturing Base & Headquarters Table 12. Global Ustekinumab Biosimilars Company, Product Type & Application Table 13. Global Ustekinumab Biosimilars Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Ustekinumab Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Subcutaneous Injection Table 18. Significant Companies of Intravenous Infusion Table 19. Global Ustekinumab Biosimilars Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Ustekinumab Biosimilars Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Ustekinumab Biosimilars Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Ustekinumab Biosimilars Sales Volume Share by Type (2021-2026) Table 23. Global Ustekinumab Biosimilars Sales Volume Share by Type (2027-2032) Table 24. Global Ustekinumab Biosimilars Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Ustekinumab Biosimilars Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Ustekinumab Biosimilars Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Ustekinumab Biosimilars Sales Value Share by Type (2021-2026) Table 28. Global Ustekinumab Biosimilars Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Crohn's Disease Table 30. Significant Companies of Ulcerative Colitis Table 31. Significant Companies of Plaque Psoriasis Table 32. Significant Companies of Psoriatic Arthritis Table 33. Significant Companies of Other Table 34. Global Ustekinumab Biosimilars Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Ustekinumab Biosimilars Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Ustekinumab Biosimilars Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Ustekinumab Biosimilars Sales Volume Share by Application (2021-2026) Table 38. Global Ustekinumab Biosimilars Sales Volume Share by Application (2027-2032) Table 39. Global Ustekinumab Biosimilars Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Ustekinumab Biosimilars Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Ustekinumab Biosimilars Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Ustekinumab Biosimilars Sales Value Share by Application (2021-2026) Table 43. Global Ustekinumab Biosimilars Sales Value Share by Application (2027-2032) Table 44. Global Ustekinumab Biosimilars Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Ustekinumab Biosimilars Sales by Region (2021-2026) & (K Units) Table 46. Global Ustekinumab Biosimilars Sales Market Share by Region (2021-2026) Table 47. Global Ustekinumab Biosimilars Sales by Region (2027-2032) & (K Units) Table 48. Global Ustekinumab Biosimilars Sales Market Share by Region (2027-2032) Table 49. Global Ustekinumab Biosimilars Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Ustekinumab Biosimilars Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Ustekinumab Biosimilars Sales Value Share by Region (2021-2026) Table 52. Global Ustekinumab Biosimilars Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Ustekinumab Biosimilars Sales Value Share by Region (2027-2032) Table 54. Global Ustekinumab Biosimilars Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Ustekinumab Biosimilars Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Ustekinumab Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Ustekinumab Biosimilars Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Ustekinumab Biosimilars Sales by Country (2021-2026) & (K Units) Table 59. Global Ustekinumab Biosimilars Sales Market Share by Country (2021-2026) Table 60. Global Ustekinumab Biosimilars Sales by Country (2027-2032) & (K Units) Table 61. Global Ustekinumab Biosimilars Sales Market Share by Country (2027-2032) Table 62. Global Ustekinumab Biosimilars Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Ustekinumab Biosimilars Sales Value Market Share by Country (2021-2026) Table 64. Global Ustekinumab Biosimilars Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Ustekinumab Biosimilars Sales Value Market Share by Country (2027-2032) Table 66. Teva Company Information Table 67. Teva Business Overview Table 68. Teva Ustekinumab Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Teva Ustekinumab Biosimilars Product Portfolio Table 70. Teva Recent Development Table 71. Amgen Company Information Table 72. Amgen Business Overview Table 73. Amgen Ustekinumab Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Amgen Ustekinumab Biosimilars Product Portfolio Table 75. Amgen Recent Development Table 76. Samsung Bioepis Company Information Table 77. Samsung Bioepis Business Overview Table 78. Samsung Bioepis Ustekinumab Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Samsung Bioepis Ustekinumab Biosimilars Product Portfolio Table 80. Samsung Bioepis Recent Development Table 81. Sandoz Company Information Table 82. Sandoz Business Overview Table 83. Sandoz Ustekinumab Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Sandoz Ustekinumab Biosimilars Product Portfolio Table 85. Sandoz Recent Development Table 86. Biocon Biologics Company Information Table 87. Biocon Biologics Business Overview Table 88. Biocon Biologics Ustekinumab Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Biocon Biologics Ustekinumab Biosimilars Product Portfolio Table 90. Biocon Biologics Recent Development Table 91. Celltrion Company Information Table 92. Celltrion Business Overview Table 93. Celltrion Ustekinumab Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Celltrion Ustekinumab Biosimilars Product Portfolio Table 95. Celltrion Recent Development Table 96. Qyuns Therapeutics Company Information Table 97. Qyuns Therapeutics Business Overview Table 98. Qyuns Therapeutics Ustekinumab Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Qyuns Therapeutics Ustekinumab Biosimilars Product Portfolio Table 100. Qyuns Therapeutics Recent Development Table 101. Bio-Thera Solutions Company Information Table 102. Bio-Thera Solutions Business Overview Table 103. Bio-Thera Solutions Ustekinumab Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Bio-Thera Solutions Ustekinumab Biosimilars Product Portfolio Table 105. Bio-Thera Solutions Recent Development Table 106. Huadong Medicine Company Information Table 107. Huadong Medicine Business Overview Table 108. Huadong Medicine Ustekinumab Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Huadong Medicine Ustekinumab Biosimilars Product Portfolio Table 110. Huadong Medicine Recent Development Table 111. Key Raw Materials Table 112. Raw Materials Key Suppliers Table 113. Ustekinumab Biosimilars Distributors List Table 114. Ustekinumab Biosimilars Customers List Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Ustekinumab Biosimilars Product Image Figure 2. Global Ustekinumab Biosimilars Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ustekinumab Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 4. Global Ustekinumab Biosimilars Sales (2021-2032) & (K Units) Figure 5. Global Ustekinumab Biosimilars Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Ustekinumab Biosimilars Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Subcutaneous Injection Image Figure 10. Intravenous Infusion Image Figure 11. Global Ustekinumab Biosimilars Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Ustekinumab Biosimilars Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Ustekinumab Biosimilars Sales Volume Share by Type (2021-2032) Figure 14. Global Ustekinumab Biosimilars Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Ustekinumab Biosimilars Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Ustekinumab Biosimilars Sales Value Share by Type (2021-2032) Figure 17. Crohn's Disease Image Figure 18. Ulcerative Colitis Image Figure 19. Plaque Psoriasis Image Figure 20. Psoriatic Arthritis Image Figure 21. Other Image Figure 22. Global Ustekinumab Biosimilars Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Ustekinumab Biosimilars Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Ustekinumab Biosimilars Sales Volume Share by Application (2021-2032) Figure 25. Global Ustekinumab Biosimilars Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Ustekinumab Biosimilars Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Ustekinumab Biosimilars Sales Value Share by Application (2021-2032) Figure 28. Global Ustekinumab Biosimilars Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Ustekinumab Biosimilars Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Ustekinumab Biosimilars Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Ustekinumab Biosimilars Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Ustekinumab Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 33. North America Ustekinumab Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Ustekinumab Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Ustekinumab Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Ustekinumab Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Ustekinumab Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Ustekinumab Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 39. South America Ustekinumab Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Ustekinumab Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Ustekinumab Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Ustekinumab Biosimilars Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Ustekinumab Biosimilars Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Subcutaneous Injection
  • Intravenous Infusion
Applications
  • Crohn's Disease
  • Ulcerative Colitis
  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Other
Companies covered
  • Teva
  • Amgen
  • Samsung Bioepis
  • Sandoz
  • Biocon Biologics
  • Celltrion
  • Qyuns Therapeutics
  • Bio-Thera Solutions
  • Huadong Medicine

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Ustekinumab Biosimilars Sales Value (2021-2032)
  4. 1.2.2 Global Ustekinumab Biosimilars Sales Volume (2021-2032)
  5. 1.2.3 Global Ustekinumab Biosimilars Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Ustekinumab Biosimilars Market Dynamics
  1. 2.1 Ustekinumab Biosimilars Industry Trends
  2. 2.2 Ustekinumab Biosimilars Industry Drivers
  3. 2.3 Ustekinumab Biosimilars Industry Opportunities and Challenges
  4. 2.4 Ustekinumab Biosimilars Industry Restraints
3 Ustekinumab Biosimilars Market by Company
  1. 3.1 Global Ustekinumab Biosimilars Company Revenue Ranking in 2025
  2. 3.2 Global Ustekinumab Biosimilars Revenue by Company (2021-2026)
  3. 3.3 Global Ustekinumab Biosimilars Sales Volume by Company (2021-2026)
  4. 3.4 Global Ustekinumab Biosimilars Average Price by Company (2021-2026)
  5. 3.5 Global Ustekinumab Biosimilars Company Ranking (2024-2026)
  6. 3.6 Global Ustekinumab Biosimilars Company Manufacturing Base and Headquarters
  7. 3.7 Global Ustekinumab Biosimilars Company Product Type and Application
  8. 3.8 Global Ustekinumab Biosimilars Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Ustekinumab Biosimilars Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Ustekinumab Biosimilars Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Ustekinumab Biosimilars Market by Type
  1. 4.1 Ustekinumab Biosimilars Type Introduction
  2. 4.1.1 Subcutaneous Injection
  3. 4.1.2 Intravenous Infusion
  4. 4.2 Global Ustekinumab Biosimilars Sales Volume by Type
  5. 4.2.1 Global Ustekinumab Biosimilars Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Ustekinumab Biosimilars Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Ustekinumab Biosimilars Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Ustekinumab Biosimilars Sales Value by Type
  9. 4.3.1 Global Ustekinumab Biosimilars Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Ustekinumab Biosimilars Sales Value by Type (2021-2032)
  11. 4.3.3 Global Ustekinumab Biosimilars Sales Value Share by Type (2021-2032)
5 Ustekinumab Biosimilars Market by Application
  1. 5.1 Ustekinumab Biosimilars Application Introduction
  2. 5.1.1 Crohn's Disease
  3. 5.1.2 Ulcerative Colitis
  4. 5.1.3 Plaque Psoriasis
  5. 5.1.4 Psoriatic Arthritis
  6. 5.1.5 Other
  7. 5.2 Global Ustekinumab Biosimilars Sales Volume by Application
  8. 5.2.1 Global Ustekinumab Biosimilars Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Ustekinumab Biosimilars Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Ustekinumab Biosimilars Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Ustekinumab Biosimilars Sales Value by Application
  12. 5.3.1 Global Ustekinumab Biosimilars Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Ustekinumab Biosimilars Sales Value by Application (2021-2032)
  14. 5.3.3 Global Ustekinumab Biosimilars Sales Value Share by Application (2021-2032)
6 Ustekinumab Biosimilars Regional Sales and Value Analysis
  1. 6.1 Global Ustekinumab Biosimilars Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Ustekinumab Biosimilars Sales by Region (2021-2032)
  3. 6.2.1 Global Ustekinumab Biosimilars Sales by Region: 2021-2026
  4. 6.2.2 Global Ustekinumab Biosimilars Sales by Region (2027-2032)
  5. 6.3 Global Ustekinumab Biosimilars Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Ustekinumab Biosimilars Sales Value by Region (2021-2032)
  7. 6.4.1 Global Ustekinumab Biosimilars Sales Value by Region: 2021-2026
  8. 6.4.2 Global Ustekinumab Biosimilars Sales Value by Region (2027-2032)
  9. 6.5 Global Ustekinumab Biosimilars Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Ustekinumab Biosimilars Sales Value (2021-2032)
  12. 6.6.2 North America Ustekinumab Biosimilars Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Ustekinumab Biosimilars Sales Value (2021-2032)
  15. 6.7.2 Europe Ustekinumab Biosimilars Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Ustekinumab Biosimilars Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Ustekinumab Biosimilars Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Ustekinumab Biosimilars Sales Value (2021-2032)
  21. 6.9.2 South America Ustekinumab Biosimilars Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Ustekinumab Biosimilars Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Ustekinumab Biosimilars Sales Value Share by Country, 2025 VS 2032
7 Ustekinumab Biosimilars Country-level Sales and Value Analysis
  1. 7.1 Global Ustekinumab Biosimilars Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Ustekinumab Biosimilars Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Ustekinumab Biosimilars Sales by Country (2021-2032)
  4. 7.3.1 Global Ustekinumab Biosimilars Sales by Country (2021-2026)
  5. 7.3.2 Global Ustekinumab Biosimilars Sales by Country (2027-2032)
  6. 7.4 Global Ustekinumab Biosimilars Sales Value by Country (2021-2032)
  7. 7.4.1 Global Ustekinumab Biosimilars Sales Value by Country (2021-2026)
  8. 7.4.2 Global Ustekinumab Biosimilars Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Ustekinumab Biosimilars Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Ustekinumab Biosimilars Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Ustekinumab Biosimilars Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Ustekinumab Biosimilars Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Ustekinumab Biosimilars Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Amgen
  8. 8.2.1 Amgen Company Information
  9. 8.2.2 Amgen Business Overview
  10. 8.2.3 Amgen Ustekinumab Biosimilars Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Amgen Ustekinumab Biosimilars Product Portfolio
  12. 8.2.5 Amgen Recent Developments
  13. 8.3 Samsung Bioepis
  14. 8.3.1 Samsung Bioepis Company Information
  15. 8.3.2 Samsung Bioepis Business Overview
  16. 8.3.3 Samsung Bioepis Ustekinumab Biosimilars Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Samsung Bioepis Ustekinumab Biosimilars Product Portfolio
  18. 8.3.5 Samsung Bioepis Recent Developments
  19. 8.4 Sandoz
  20. 8.4.1 Sandoz Company Information
  21. 8.4.2 Sandoz Business Overview
  22. 8.4.3 Sandoz Ustekinumab Biosimilars Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sandoz Ustekinumab Biosimilars Product Portfolio
  24. 8.4.5 Sandoz Recent Developments
  25. 8.5 Biocon Biologics
  26. 8.5.1 Biocon Biologics Company Information
  27. 8.5.2 Biocon Biologics Business Overview
  28. 8.5.3 Biocon Biologics Ustekinumab Biosimilars Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Biocon Biologics Ustekinumab Biosimilars Product Portfolio
  30. 8.5.5 Biocon Biologics Recent Developments
  31. 8.6 Celltrion
  32. 8.6.1 Celltrion Company Information
  33. 8.6.2 Celltrion Business Overview
  34. 8.6.3 Celltrion Ustekinumab Biosimilars Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Celltrion Ustekinumab Biosimilars Product Portfolio
  36. 8.6.5 Celltrion Recent Developments
  37. 8.7 Qyuns Therapeutics
  38. 8.7.1 Qyuns Therapeutics Company Information
  39. 8.7.2 Qyuns Therapeutics Business Overview
  40. 8.7.3 Qyuns Therapeutics Ustekinumab Biosimilars Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Qyuns Therapeutics Ustekinumab Biosimilars Product Portfolio
  42. 8.7.5 Qyuns Therapeutics Recent Developments
  43. 8.8 Bio-Thera Solutions
  44. 8.8.1 Bio-Thera Solutions Company Information
  45. 8.8.2 Bio-Thera Solutions Business Overview
  46. 8.8.3 Bio-Thera Solutions Ustekinumab Biosimilars Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Bio-Thera Solutions Ustekinumab Biosimilars Product Portfolio
  48. 8.8.5 Bio-Thera Solutions Recent Developments
  49. 8.9 Huadong Medicine
  50. 8.9.1 Huadong Medicine Company Information
  51. 8.9.2 Huadong Medicine Business Overview
  52. 8.9.3 Huadong Medicine Ustekinumab Biosimilars Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Huadong Medicine Ustekinumab Biosimilars Product Portfolio
  54. 8.9.5 Huadong Medicine Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Ustekinumab Biosimilars Value Chain Analysis
  2. 9.1.1 Ustekinumab Biosimilars Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Ustekinumab Biosimilars Sales Mode & Process
  6. 9.2 Ustekinumab Biosimilars Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Ustekinumab Biosimilars Distributors
  9. 9.2.3 Ustekinumab Biosimilars Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst